Sacubitril/Valsartan

Long Term Outcomes with Sacubitril Valsartan in HFrEF: Insights From a Real World Cohort

by Prateek Chopra | June 1, 2026 | Cardiology Conferences | ESC-HF 2026 Sacubitril–valsartan (SV) has shown prognostic benefits in patients with heart failure with reduced ejection fraction (HFrEF), although its long-term real-world impact remains unclear. This study assessed long-term outcomes associated with SV use in a real-world HFrEF cohort. The findings were presented at Heart Failure 2026, organized by the […]

Long Term Outcomes with Sacubitril Valsartan in HFrEF: Insights From a Real World Cohort Read Post »

Leave a Comment / ESC-HF Day 4 / bluetree.healthcare@gmail.com / July 30, 2026 / Guideline-Directed Medical Therapy (GDMT), Heart Failure Prognosis, Heart Failure with Reduced Ejection Fraction (HFrEF), Sacubitril/Valsartan, SGLT2 Inhibitors

The Positive Effect of Sacubitril/Valsartan Therapy on QRS Width and QTC Interval on Electrocardiogram in Heart Failure Patients With Reduced Ejection Fraction

by Prateek Chopra | June 1, 2026 | Cardiology Conferences | ESC-HF 2026 Sacubitril/valsartan (S/V) therapy has been shown to reduce hospitalizations, improve echocardiographic parameters, and lower mortality in patients with heart failure with reduced ejection fraction (HFrEF; EF <40%). S/V therapy has also been associated with reductions in ventricular tachycardia episodes and premature ventricular contractions. However, the precise mechanism underlying

The Positive Effect of Sacubitril/Valsartan Therapy on QRS Width and QTC Interval on Electrocardiogram in Heart Failure Patients With Reduced Ejection Fraction Read Post »

Leave a Comment / ESC-HF Day 4 / bluetree.healthcare@gmail.com / July 30, 2026 / Electrocardiogram (ECG), Heart Failure with Reduced Ejection Fraction (HFrEF), QRS Duration, QTc Interval, Sacubitril/Valsartan

Impact of Sacubitril/Valsartan on Lipid Parameters in Pa ents with Heart Failure with Reduced Ejection Fraction

by Prateek Chopra | May 28, 2026 | Cardiology Conferences | ESC-HF 2026 Long-term modulation of lipid metabolism with angiotensin receptor–neprilysin inhibition in heart failure with reduced ejection fraction remains incompletely characterised, despite evidence suggesting metabolic effects mediated through neprilysin inhibition and enhanced natriuretic peptide signalling. This study evaluated the longitudinal effects of sacubitril/valsartan on lipid parameters and N-terminal pro-B-type natriuretic

Impact of Sacubitril/Valsartan on Lipid Parameters in Pa ents with Heart Failure with Reduced Ejection Fraction Read Post »

Leave a Comment / ESC-HF Day 3 / bluetree.healthcare@gmail.com / July 30, 2026 / Angiotensin Receptor-Neprilysin Inhibitor (ARNI), Heart Failure with Reduced Ejection Fraction (HFrEF), Lipid Metabolism, NT-proBNP, Sacubitril/Valsartan